Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

BACKGROUND: Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. MATERIALS, AND METHODS: Hepatic adverse reactions (ARs) were assessed by type and magnitude o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, James H., Gelderblom, Hans, van de Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia‐Chi, Baba, Hideo A., Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Sarcomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100574/
https://www.ncbi.nlm.nih.gov/pubmed/33289960
http://dx.doi.org/10.1002/onco.13629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100574/
https://www.ncbi.nlm.nih.gov/pubmed/33289960
http://dx.doi.org/10.1002/onco.13629

Ejemplares similares